Neoadjuvant Systemic Therapy: A New Approach to Head and Neck Cancer Treatment
A groundbreaking clinical trial is underway, funded by the National Cancer Institute, to explore a novel approach to treating recurrent head and neck cancer. This trial aims to revolutionize the standard of care for a patient population that faces a grim prognosis. Up to 40% of head and neck squamous cell carcinoma patients experience recurrence after radiation therapy, and surgery, the current standard treatment, often results in poor survival rates.
The trial's primary focus is to determine if neoadjuvant systemic therapy, which includes chemotherapy and immunotherapy, can significantly improve survival outcomes for these patients. This innovative approach involves administering therapy before surgery, potentially extending disease-free and overall survival.
Dr. Christina Henson, an associate professor at the University of Oklahoma College of Medicine and a radiation oncologist at the OU Health Stephenson Cancer Center, emphasizes the trial's importance. She states, 'Surgical intervention for recurrence, while potentially curative, is often profoundly debilitating and is still associated with suboptimal survival. This trial seeks to determine if systemic therapy administered prior to surgery can extend disease-free and overall survival for these patients.'
Trial Design and Treatment Arms
Eligible patients, who are candidates for salvage surgery, will be randomly assigned to one of three treatment arms. The first arm involves neoadjuvant chemotherapy with carboplatin and paclitaxel. In the second arm, patients receive neoadjuvant chemotherapy combined with the anti–PD-L1 immunotherapy cemiplimab (Libtayo). The third arm involves surgery alone.
The trial's design is meticulous, with specific treatment protocols for each arm. In arm one, patients receive paclitaxel and carboplatin intravenously (IV) on day one of each cycle, with cycles repeating every 21 days for two cycles, provided there is no disease progression or unacceptable toxicity. Arm two involves a similar regimen but with the addition of cemiplimab. Arm three, the surgery arm, is the standard of care.
After the initial treatment, patients are followed up at specific intervals, ensuring comprehensive post-treatment care. The trial's primary objective is to measure event-free survival (EFS) for patients treated with chemotherapy or chemo-immunotherapy before salvage surgery compared to those undergoing standard surgery.
Secondary objectives include disease-free survival (DFS), overall survival (OS), and distant metastasis. Exploratory outcomes will also be assessed, providing valuable insights into the effectiveness of this novel treatment approach.
Technical Precision and Consistency
The trial's success relies on technical precision and consistency in radiotherapy parameters across participating sites. Dr. Mark Newpower, an assistant professor at the OU College of Medicine and the lead proton physicist at the Stephenson Cancer Center, highlights the importance of this aspect. He states, 'Our contribution has focused on ensuring the technical precision and consistency of radiotherapy parameters across participating sites, which is vital for a multi-institutional study of this nature.'
Stay Informed and Engaged
Stay tuned for updates on this groundbreaking trial, as it has the potential to change the landscape of head and neck cancer treatment. The trial's findings will provide valuable insights into the effectiveness of neoadjuvant systemic therapy and its role in improving survival outcomes for patients with recurrent head and neck cancer.
